Rapid-Turnaround Co-Administration of mRNA-Based MHC-I and MHC-II-Restricted Neoantigens Enhances Immune Responses of Antigen-Specific CD8⁺ T Cells and Anti-Cancer Efficacy in Colorectal Cancer.

ABSTRACT: Personalized cancer vaccines (PCVs) represent a promising frontier in cancer immunotherapy; however, challenges in neoantigen prediction and treatment optimization persist. This study aims to introduce an innovative mRNA-based PCV platform that addresses these limitations. Co-administration of our major histocompatibility complex (MHC)-I and MHC-II-restricted neoantigens increases antigen-specific T cell responses and exhibits strong anti-cancer efficacy, significantly inducing antigen-specific CD8⁺ T cell-immune responses. The mRNA-based vaccine targeting the novel antigens demonstrates anti-tumor efficacy in a murine model of colorectal cancer and reduces post-surgery recurrence in mRNA-vaccinated mice. Notably, early-stage vaccination induces a striking anti-cancer effect, un

SUBMITTER: Cho S 

PROVIDER: S-EPMC12533368 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature